Related Experiment Videos
Lubeluzole for acute ischaemic stroke
C Gandolfo1, P Sandercock, M Conti
1Neuroscience and Neurorehabilitation, School of Medicine - University of Genoa, Via De Toni 5, Genoa, Liguria, Italy, 16132. gandcaci@csita.unige.it
The Cochrane Database of Systematic Reviews
|March 1, 2002
Summary
Lubeluzole did not reduce death or dependency in acute ischemic stroke patients. However, it was linked to an increased risk of heart conduction disorders, specifically prolonged Q-T intervals.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Ischemic stroke involves excessive glutamate release and impaired re-uptake.
- Preclinical models show neuroprotection with glutamate antagonists.
- Lubeluzole, a neuroprotective agent, inhibits glutamate release and ion channels.
Purpose of the Study:
- To evaluate the effectiveness and safety of lubeluzole in acute ischemic stroke patients.
- To assess lubeluzole's impact on mortality and dependency.
- To identify potential adverse events associated with lubeluzole treatment.
Main Methods:
- Systematic review of randomized controlled trials.
- Searched Cochrane Stroke Group, CENTRAL, Medline, Embase, Pascal BioMed, and Current Contents.
- Included trials compared intravenous lubeluzole with placebo or open control in acute ischemic stroke patients.
Main Results:
- Five trials with 3,510 patients were analyzed.
- Lubeluzole (5-20 mg/day for 5 days) showed no significant reduction in all-cause mortality (OR=0.93) or death/dependency (OR=1.04).
- Lubeluzole was associated with a significant increase in heart conduction disorders, specifically prolonged Q-T intervals (OR=1.43).
Conclusions:
- Lubeluzole is not effective in reducing death or dependency in acute ischemic stroke.
- Lubeluzole treatment is associated with a significant increase in heart conduction abnormalities.
- The use of lubeluzole in acute ischemic stroke warrants caution due to cardiac side effects.